Key points from article :
A new personalized mRNA vaccine trial is underway in the UK to combat melanoma, the deadliest form of skin cancer.
The first-ever patient received the shot, which help his immune system wipe out cancer cells.
The vaccine (mRNA-4157) is created based on the unique genetic makeup of the patient's tumor.
It instructs the body to attack specific markers only found on cancerous cells.
UCLH doctors are giving it alongside another drug, pembrolizumab/Keytruda, that also helps the immune system kill cancer cells
They believe this personalized approach has the potential to cure melanoma and other cancers.
The trial is currently in phase III and is also being conducted in other countries like Australia.
Early results show promise, with a nearly 50% reduction in recurrence rates for patients receiving the vaccine.
The UK arm of the trial aims to recruit 60-70 patients across various cities
